In an attempt to strengthen its rare disease portfolio, ANI Pharmaceuticals has agreed to acquire Alimera Sciences for US$381 M. Through the takeover, ANI will gain access to Alimera’s two commercial products, Iluvien® and Yutiq®, which are treatments for diabetic macular edema (DME) and non-infectious uveitis in the posterior segment (NIU-PS). The deal will further assist ANI in extending its reach beyond the US by integrating Alimera’s direct marketing operations and partnerships in Europe, Asia, and the Middle East. The transaction is expected to complete by the third quarter of 2024.